Molecular Docking and in Silico Pharmacokinetic Analysis of Peronemin As A Potential 17β-Hsd1 Inhibitor For Estrogen-Dependent Cancer Therapy
DOI:
https://doi.org/10.33394/hjkk.v13i6.18780Abstract
High levels of estradiol (E2) are important in the development of endometrial cancer. This hormone is mostly produced when the enzyme 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) changes estrone (E1) into estradiol (E2). Inhibiting this enzyme can reduce estrogen production in cancers that rely on estrogen. This study examined three Peronemin derivatives (A2, A3, C1) as potential 17β-HSD1 inhibitors through detailed computer analysis. PASS predictions showed these compounds likely have antineoplastic activity (Pa > 0.85). Their physicochemical properties, based on Lipinski's rule, suggest they have good ADME profiles, with high gastrointestinal absorption and a predicted ability to cross the blood-brain barrier.Molecular docking results showed that all three compounds interacted stably with the 17β-HSD1 active site. Peronemin C1 had the strongest binding (ΔG = -6.56 kcal-mol-¹; Ki = 15.56 μM). Mapping the interactions revealed that A2 formed hydrogen bonds with Tyr155, A3 formed hydrogen bonds with Lys159, and C1 exhibited strong hydrophobic interactions. The results suggest that Peronemin A2, A3, and especially C1 could be promising for further development as 17β-HSD1 inhibitors. However, further laboratory studies are needed to confirm the effectiveness of these compounds and determine their practical application.
Downloads
Published
How to Cite
Issue
Section
License
License and Publishing Agreement
In submitting the manuscript to the journal, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- That its publication has been approved by all the author(s) and by the responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and publishing agreement.
Copyright
Authors who publish with Hydrogen: Jurnal Kependidikan Kimia agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.Â
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Licensing for Data Publication
Hydrogen: Jurnal Kependidikan Kimia uses a variety of waivers and licenses, that are specifically designed for and appropriate for the treatment of data: Open Data Commons Attribution License, http://www.opendatacommons.org/licenses/by/1.0/ (default) Other data publishing licenses may be allowed as exceptions (subject to approval by the editor on a case-by-case basis) and should be justified with a written statement from the author, which will be published with the article.
